CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net loss	$ (28,457)	$ (17,750)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,643	1,255
Depreciation and amortization	1,144	1,406
Loss on disposal of property and equipment	4
Gain on sale of Aptevo BioTherapeutics		(14,338)
Loss on extinguishment of debt		2,104
Non-cash interest expense and other	6,642	411
Changes in operating assets and liabilities:
Royalty receivable	(1,295)	(2,369)
Prepaid expenses and other current assets	436	(1,112)
Operating lease right-of-use asset	1,138	1,025
Accounts payable, accrued compensation and other liabilities	(1,915)	(702)
Long-term operating lease liability	(1,019)	(967)
Change in assets and liabilities held for sale		1,719
Net cash used in operating activities	(21,679)	(29,318)
Investing Activities
Purchases of property and equipment	(713)	(88)
Cash received from sale of Aptevo BioTherapeutics		28,120
Net cash (used in) provided by investing activities	(713)	28,032
Financing Activities
Proceeds from other long-term obligations, net of issuance costs		24,731
Payments of long-term debt, including exit and other fees	(10,550)	(22,104)
Repayments under liability related to sale of future royalties	(8,627)
Proceeds from sale of future royalties	35,000
Transaction costs from sale of future royalties	(1,100)
Proceeds from exercises of stock options	220	23
Proceeds from exercises of warrants	985	21,235
Proceeds from common stock issued pursuant to the Lincoln Park Purchase Agreement	10,233
Payment of tax liability for vested equity awards		(11)
Net cash provided by financing activities from continuing operations	26,161	23,874
Increase in cash, cash equivalents, and restricted cash	3,769	22,588
Cash, cash equivalents, and restricted cash at beginning of period	42,534	19,946
Cash, cash equivalents, and restricted cash at end of period	$ 46,303	$ 42,534